BACKGROUND Bacterial vaginosis (BV) is one of the common vaginal infections among childbearing women. The usual treatment for BV is metronidazole; hence 30% of women have recurrence within 60 to 90 days after treatment. There are some studies which assessed the effect of secnidazole on BV. The aim of this systematic review was to investigate the effectiveness of secnidazole for treatment of BV. METHODS The Cochrane Library, MEDLINE (PubMed), Scopus, and Web of Science (all databases from inception till October 28, 2018) were searched. Primary outcomes were clinical cure rate and microbiologic cure rate and the secondary outcomes were adverse events. Data was extracted from eligible studies by two review authors individually and analyzed by RevMan 5.3. RESULTS Our search found six trials involving 1528 participants. Treatment with 2 g secnidazole could significantly reduce the risk of BV in patients with three or less episodes of BV in the last year by OR: 7.54 (95% CI, 3.89-14.60, p < 0.00001) and in patients with four or more episodes of BV in the last year (OR: 4.74, 95% CI: 1.51-14.84, p = 0.0.008). Secnidazole (2 g) could significantly increase the microbiologic cure rate in women with 3 or less episodes of BV in the last year (OR: 7.63, 95% CI: 2.30-25.33, p = 0.0009) but not in the women with 4 or more episodes of BV in the last year (OR: 20.17, 95% CI: 1.06-382.45, p = 0.05). The clinical cure rate, microbiological effect and the therapeutic cure rate of 2 g secnidazole was significantly more than that of 1 g secnidazole. The results showed that the clinical cure rate of 2 g secnidazole was not different from the following medications: metronidazole (500 mg bid for 5 days), secnidazole plus vaginal metronidazole, 2 g single dose of oral metronidazole and 2 g secnidazole plus vaginal ornidazole. CONCLUSION This review showed that 2 g and 1 g secnidazole were better than placebo, however, 2 g secnidazole was more effective than 1 g. Secnidazole 2 g was not different from metronidazole (500 mg bid for 5 days), or from secnidazole plus vaginal metronidazole, or 2 g single dose of oral metronidazole or from 2 g secnidazole plus vaginal ornidazole.

中文翻译：

---

塞尼达唑治疗细菌性阴道病的系统评价。

背景技术细菌性阴道病（BV）是育龄妇女中常见的阴道感染之一。BV的常用治疗方法是甲硝唑；因此，有30％的女性在治疗后60至90天内复发。有一些研究评估了塞尼达唑对BV的作用。该系统评价的目的是研究塞尼达唑治疗BV的有效性。方法搜索Cochrane图书馆，MEDLINE（PubMed），Scopus和Web of Science（从成立到2018年10月28日的所有数据库）。主要结局为临床治愈率和微生物学治愈率，次要结局为不良事件。数据由两名评价作者分别从符合条件的研究中提取，并通过RevMan 5.3进行分析。结果我们的搜索发现了6项试验，涉及1528名参与者。去年通过3例或少于3例BV发作的患者使用2克塞尼达唑治疗可以显着降低BV的风险，其结果是：7.54（95％CI，3.89-14.60，p <0.00001）和4例或以上发作的患者去年的BV（OR：4.74，95％CI：1.51-14.84，p = 0.0.008）。塞尼达唑（2 g）可以显着提高去年BV发作3次或以下的女性的微生物学治愈率（OR：7.63，95％CI：2.30-25.33，p = 0.0009），但对于4岁或3岁以下的女性则不能去年有更多的BV发作（或：20.17，95％CI：1.06-382.45，p = 0.05）。2克塞硝唑的临床治愈率，微生物学效果和治疗治愈率显着高于1克塞硝唑。结果表明，2 g塞尼达唑的临床治愈率与以下药物并无差异：甲硝唑（500毫克出价5天），塞尼达唑加阴道甲硝唑，2克单剂口服甲硝唑和2克塞尼达唑加阴道甲硝唑。结论这项评价表明2克和1克的塞硝唑比安慰剂更好，但是2克的塞硝唑比1克更有效。塞克硝唑2克与甲硝唑（500毫克，连续5天注射），塞尼替唑加阴道甲硝唑，2克单剂口服甲硝唑或2克塞尼达唑加阴道甲硝唑没有区别。